183 related articles for article (PubMed ID: 32923120)
1. Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome.
Brunekreeft KL; Paijens ST; Wouters MCA; Komdeur FL; Eggink FA; Lubbers JM; Workel HH; Van Der Slikke EC; Pröpper NEJ; Leffers N; Adam J; Pijper H; Plat A; Kol A; Nijman HW; De Bruyn M
Oncoimmunology; 2020 May; 9(1):1760705. PubMed ID: 32923120
[TBL] [Abstract][Full Text] [Related]
2. Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.
Khairallah AS; Genestie C; Auguste A; Leary A
Int J Cancer; 2018 Jul; 143(1):8-15. PubMed ID: 29218796
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
4. Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study.
Cao G; Hua D; Li J; Zhang X; Zhang Z; Zhang B; Bei T; Cui L; Chen S; Wang S; Zhu L
Front Immunol; 2023; 14():1022942. PubMed ID: 36993949
[TBL] [Abstract][Full Text] [Related]
5. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
7. Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer.
Jäntti T; Luhtala S; Mäenpää J; Staff S
Tumour Biol; 2020 Nov; 42(11):1010428320971404. PubMed ID: 33169632
[TBL] [Abstract][Full Text] [Related]
8. Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer.
Liu M; Tayob N; Penter L; Sellars M; Tarren A; Chea V; Carulli I; Huang T; Li S; Cheng SC; Le P; Frackiewicz L; Fasse J; Qi C; Liu JF; Stover EH; Curtis J; Livak KJ; Neuberg D; Zhang G; Matulonis UA; Wu CJ; Keskin DB; Konstantinopoulos PA
Clin Cancer Res; 2022 Aug; 28(15):3356-3366. PubMed ID: 35443043
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Kim HS; Kim JY; Lee YJ; Kim SH; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Gynecol Oncol; 2018 Dec; 151(3):414-421. PubMed ID: 30314669
[TBL] [Abstract][Full Text] [Related]
10. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
[TBL] [Abstract][Full Text] [Related]
11. The Putative Effects of Neoadjuvant Chemotherapy on the Immune System of Advanced Epithelial Ovarian Carcinoma.
Li Y; Gan X; Li F; Hu L
Immunol Invest; 2024 Feb; 53(2):91-114. PubMed ID: 37987679
[TBL] [Abstract][Full Text] [Related]
12. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Provencher DM; Gallagher CJ; Parulekar WR; Ledermann JA; Armstrong DK; Brundage M; Gourley C; Romero I; Gonzalez-Martin A; Feeney M; Bessette P; Hall M; Weberpals JI; Hall G; Lau SK; Gauthier P; Fung-Kee-Fung M; Eisenhauer EA; Winch C; Tu D; MacKay HJ
Ann Oncol; 2018 Feb; 29(2):431-438. PubMed ID: 29186319
[TBL] [Abstract][Full Text] [Related]
13. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
15. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS
J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360
[TBL] [Abstract][Full Text] [Related]
16. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
17. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.
Leary A; Genestie C; Blanc-Durand F; Gouy S; Dunant A; Maulard A; Drusch F; Cheaib B; Michels J; Bentivegna E; LeFormal A; Mesnage S; Morice P; Pautier P; Khairallah AS
Cancer Immunol Immunother; 2021 Feb; 70(2):519-531. PubMed ID: 32852603
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer.
Heeren AM; van Luijk IF; Lakeman J; Pocorni N; Kole J; de Menezes RX; Kenter GG; Bosse T; de Kroon CD; Jordanova ES
Cancer Immunol Immunother; 2019 Nov; 68(11):1759-1767. PubMed ID: 31616965
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
